SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19
Open accessThe DOI matches its Crossref record.
Abstract
To the Editor Since the outbreak of the SARS-CoV-2 pandemic, there have been many reports of autoimmune diseases triggered by or related to COVID-19 such as Guillain–Barre’s syndrome, autoimmune haemolytic anaemia, autoimmune thrombotic thrombocytopenic purpura or autoimmune thrombocytopenic purpura. Regarding thyroid disease, there have been three case reports of subacute thyroiditis [1–3] but, as far as we know, there have been no reports about autoimmune hyperthyroidism. We hereby describe two cases of autoimmune hyperthyroidism (Graves’ disease) occurring after SARS-CoV-2 infection. A 60-year-old woman with a previous diagnosis of Graves’ disease at the age of 23 years, treated with thiamazole and who had been in remission since the age of 25 years with a normal thyroid function on the last checkup (September 2019). She presented to the primary care center with dyspnoea and chest pain in April 16th, 2020. A naso-pharyngeal swab test for SARS-CoV-2 was negative but lung ultrasound showed an interstitial pattern compatible with COVID-19 pneumonia and both IgM and IgG against SARS-CoV-2 were positive 4 days later. After clinical improvement, she presented to the emergency room on May 25th, 2020, with palpitations, nervousness and fatigue. Thyroid function was assessed, showing suppressed TSH (< 0.01 mIU/mL, normal range 0.3–5), normal free thyroxine (FT4 16 pmol/L, normal range 9–19) and elevated free triiodothyronine (FT3 7.93 pmol/L, normal range 2.63–5.7). Upon physical examination, no goiter was found and she referred no cervical pain. TSH receptor antibodies were positive (2.13 IU/L, normal range < 1.75) and thyroperoxidase and thyroglobulin antibodies were also positive (1343 IU/ mL, normal range < 100; 199 IU/mL, normal range < 138; respectively). Thyroid iodine uptake was increased to 30% and 45.7% at 2 and 24 h after administration of 100 μCi of iodine (I131). A 53-year-old woman experienced dyspnoea and fever starting on March 17th, 2020. A naso-pharyngeal swab test for SARS-CoV-2 was negative but chest X-ray showed bilateral interstitial pneumonia compatible with COVID-19. She did not require hospitalisation and was treated symptomatically. No iodine-containing drugs were given. Infection by SARS-CoV-2 was later confirmed by positive IgG on April 20th, 2020. Due to persisting asthenia and onset of tremor and palpitations, thyroid function was assessed on May 21st, 2020, showing suppressed serum TSH (< 0.01 mIU/mL) with increased serum-free thyroxine (FT4 36.5 pmol/L). Physical examination revealed a non-tender goiter. TSH receptor antibodies were positive (6.07 IU/L), as well as thyroperoxidase and thyroglobulin antibodies (3239 IU/mL and 1617 IU/mL, respectively). Iodine-uptake was increased to 61 and 62% at 2 and 24 h respectively. Therapy with thiamazole and propranolol was started to both patients with improvement of symptoms and thyroid function. Clinical presentation, increased thyroid uptake and positive TSH receptor antibodies are compatible with a diagnosis of Graves’ disease (autoimmune hyperthyroidism). Both cases of hyperthyroidism were diagnosed 1 and 2 months after the clinical onset of COVID-19. In conclusion, we report two cases of Graves’ disease after COVID-19, one with a previous history of Graves’ disease in remission for more than 30 years, and another with no previous known thyroid disease. Of course, with Graves’ disease being the most frequent cause of hyperthyroidism, especially in middle-aged women, the association might be * M. Mateu-Salat m.mateu7@gmail.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
Pathological sequelae of long-haul COVID
Mehandru, S., & Merad, M. (2022) · Nature Immunology · doi:10.1038/s41590-021-01104-y · Cited by 657
The SARS-CoV-2 as an instrumental trigger of autoimmunity
Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., & Shoenfeld, Y. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102792 · Cited by 494
Impact of COVID-19 on the thyroid gland: an update
Scappaticcio, L., Pitoia, F., Esposito, K., Piccardo, A., & Trimboli, P. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09615-z · Cited by 259
Metadata
- Authors
- Mateu-Salat, M., Urgell, E., & Chico, A.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2020-07-19
- Volume
- 43
- Issue
- 10
- Pages
- 1527-1528
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W3042907391
- Cited by
- 213
- References
- 0
- FWCI
- 26.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. https://app.cochat.ai/papers/10.1007/s40618-020-01366-7
- The paper
- Mateu-Salat, M., Urgell, E., & Chico, A. (2020). SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-020-01366-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.